Our areas of partnering interest
Are you wondering whether your novel science or technology may be of interest to AstraZeneca? Here is a summary of the key areas in which we are keen to explore collaboration opportunities.
-
Oncology
-
Cardiovascular, renal and metabolism
-
Respiratory
-
Inflammation and Autoimmunity
-
Precision Medicine
-
Enabling technologies
Oncology
Our ambition in Oncology is to push the boundaries of science to change the practice of medicine, transform the lives of patients living with cancer, and ultimately eliminate cancer as a cause of death. To do this, we focus on four established scientific platforms – immunotherapy, the genetic drivers of cancer and resistance, DNA damage response, and antibody drug conjugates. Our goal is to continue to bring a solid flow of innovative medicines to patients and physicians all over the world.
Cardiovascular, Renal and Metabolism
In cardiovascular, renal and metabolic disease, we are deepening our understanding not only of individual conditions, such as heart disease and diabetes, but also how they interact with and impact one another. Our aim is to move from slowing diseases and protecting organs to stopping diseases and regenerating organs.
Respiratory
In respiratory, we will continue improving our core offering of inhaled medicines to control symptoms, while pushing ahead with new biologics therapies for specific patient populations. With our early research, we aim for scientific breakthroughs to produce truly disease-modifying medicines which transform standards of care.
Inflammation and Autoimmunity
Our research efforts are focused on gaining a better understanding of the common biology and shared molecular pathways among inflammatory and autoimmune diseases, as well as the fundamental drivers and mechanisms of disease. Our aim is to identify and select drug targets with potential to effectively treat multiple diseases.
Precision Medicine
More than 90 percent of our pipeline now follows a precision medicine approach. We collaborate with a wide range of experts to identify, validate and develop diagnostics to regulatory standards globally, and to commercialise innovative biomarker capabilities for patient selection, disease identification, pharmacological assessment and drug response monitoring.
Enabling technologies
We are interested in cutting-edge technologies to enhance the quality, effectiveness and productivity of our research and translational capabilities.
Collaboration opportunities in China and other international markets
No matter where in the world you may be located, we are interested in exploring leading-edge collaboration opportunities with you – across our main therapy areas and beyond. We carefully consider local medical circumstances and adopt a flexible approach that enables us to meet specific patient needs in key markets.
In China, for example, we are exploring opportunities that support and enhance our existing commercial strength. Our focus is on partnering opportunities at or near commercial launch stage, in areas such as pediaetric, nebulised, pulmonary, gastric, cardiovascular, and traditional Chinese medicine. Our interest goes beyond pharmaceutical products to diagnostics, devices, and digital technologies. We aim to work with a range of partners to build end-to-end patient solutions that help improve disease awareness, diagnosis, treatment and post-treatment care. While these partnerships are designed to meet the unmet medical needs of local patients, some also have potential to benefit patients globally.
Using our presence and reach, we can also help you commercialise your product in China and other international markets.
Our remarkable progress and presence in China
#2
pharmaceutical company in China*
2nd biggest
national market for AstraZeneca
13,000+
employees throughout China
$3,795m
Product Sales in 2018
Fastest-growing
top 10 multinational company in China in 2018
*Measured by value in the hospital sector (by sales)
Veeva ID: Z4-21503
Date of Prep: Dec 2019
Expiry Date: Dec 2020